![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SFRP2 |
Gene summary for SFRP2 |
![]() |
Gene information | Species | Human | Gene symbol | SFRP2 | Gene ID | 6423 |
Gene name | secreted frizzled related protein 2 | |
Gene Alias | FRP-2 | |
Cytomap | 4q31.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A140VJU3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6423 | SFRP2 | LZE2T | Human | Esophagus | ESCC | 2.55e-26 | 1.68e+00 | 0.082 |
6423 | SFRP2 | LZE4T | Human | Esophagus | ESCC | 2.98e-10 | -1.90e-01 | 0.0811 |
6423 | SFRP2 | P9T-E | Human | Esophagus | ESCC | 1.27e-04 | 2.22e+00 | 0.1131 |
6423 | SFRP2 | P16T-E | Human | Esophagus | ESCC | 1.64e-04 | -2.73e-01 | 0.1153 |
6423 | SFRP2 | P24T-E | Human | Esophagus | ESCC | 6.01e-05 | 3.47e-01 | 0.1287 |
6423 | SFRP2 | P31T-E | Human | Esophagus | ESCC | 2.95e-04 | -1.12e-01 | 0.1251 |
6423 | SFRP2 | P39T-E | Human | Esophagus | ESCC | 2.46e-03 | 1.80e-02 | 0.0894 |
6423 | SFRP2 | P48T-E | Human | Esophagus | ESCC | 1.63e-04 | -2.97e-01 | 0.0959 |
6423 | SFRP2 | P49T-E | Human | Esophagus | ESCC | 8.30e-28 | 1.16e+00 | 0.1768 |
6423 | SFRP2 | P52T-E | Human | Esophagus | ESCC | 2.82e-02 | 1.61e-01 | 0.1555 |
6423 | SFRP2 | P54T-E | Human | Esophagus | ESCC | 4.23e-20 | -1.50e-01 | 0.0975 |
6423 | SFRP2 | P62T-E | Human | Esophagus | ESCC | 5.31e-03 | -3.00e-01 | 0.1302 |
6423 | SFRP2 | P74T-E | Human | Esophagus | ESCC | 1.44e-02 | -2.56e-01 | 0.1479 |
6423 | SFRP2 | P75T-E | Human | Esophagus | ESCC | 1.17e-03 | -1.04e-01 | 0.1125 |
6423 | SFRP2 | P127T-E | Human | Esophagus | ESCC | 1.18e-03 | -2.91e-01 | 0.0826 |
6423 | SFRP2 | C21 | Human | Oral cavity | OSCC | 1.13e-03 | 5.20e-02 | 0.2678 |
6423 | SFRP2 | C30 | Human | Oral cavity | OSCC | 1.07e-10 | 3.45e-01 | 0.3055 |
6423 | SFRP2 | C51 | Human | Oral cavity | OSCC | 7.17e-05 | 3.30e-01 | 0.2674 |
6423 | SFRP2 | C09 | Human | Oral cavity | OSCC | 1.41e-06 | 9.04e-02 | 0.1431 |
6423 | SFRP2 | LP15 | Human | Oral cavity | LP | 1.59e-02 | 1.74e+00 | 0.2174 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00456006 | Oral cavity | OSCC | positive regulation of fat cell differentiation | 41/7305 | 66/18723 | 1.20e-04 | 8.60e-04 | 41 |
GO:00606066 | Oral cavity | OSCC | tube closure | 52/7305 | 89/18723 | 1.59e-04 | 1.10e-03 | 52 |
GO:005134618 | Oral cavity | OSCC | negative regulation of hydrolase activity | 182/7305 | 379/18723 | 1.98e-04 | 1.32e-03 | 182 |
GO:001097510 | Oral cavity | OSCC | regulation of neuron projection development | 210/7305 | 445/18723 | 2.35e-04 | 1.52e-03 | 210 |
GO:001095117 | Oral cavity | OSCC | negative regulation of endopeptidase activity | 126/7305 | 252/18723 | 2.37e-04 | 1.54e-03 | 126 |
GO:001046618 | Oral cavity | OSCC | negative regulation of peptidase activity | 130/7305 | 262/18723 | 2.89e-04 | 1.82e-03 | 130 |
GO:006007010 | Oral cavity | OSCC | canonical Wnt signaling pathway | 148/7305 | 303/18723 | 2.89e-04 | 1.82e-03 | 148 |
GO:00182123 | Oral cavity | OSCC | peptidyl-tyrosine modification | 180/7305 | 378/18723 | 3.63e-04 | 2.22e-03 | 180 |
GO:00018388 | Oral cavity | OSCC | embryonic epithelial tube formation | 66/7305 | 121/18723 | 3.70e-04 | 2.26e-03 | 66 |
GO:00073697 | Oral cavity | OSCC | gastrulation | 95/7305 | 185/18723 | 4.17e-04 | 2.54e-03 | 95 |
GO:00301983 | Oral cavity | OSCC | extracellular matrix organization | 146/7305 | 301/18723 | 4.67e-04 | 2.77e-03 | 146 |
GO:003514810 | Oral cavity | OSCC | tube formation | 78/7305 | 148/18723 | 4.82e-04 | 2.85e-03 | 78 |
GO:00018377 | Oral cavity | OSCC | epithelial to mesenchymal transition | 82/7305 | 157/18723 | 5.09e-04 | 2.98e-03 | 82 |
GO:00452293 | Oral cavity | OSCC | external encapsulating structure organization | 147/7305 | 304/18723 | 5.30e-04 | 3.08e-03 | 147 |
GO:00430623 | Oral cavity | OSCC | extracellular structure organization | 146/7305 | 302/18723 | 5.59e-04 | 3.23e-03 | 146 |
GO:005067810 | Oral cavity | OSCC | regulation of epithelial cell proliferation | 180/7305 | 381/18723 | 5.88e-04 | 3.35e-03 | 180 |
GO:00605609 | Oral cavity | OSCC | developmental growth involved in morphogenesis | 116/7305 | 234/18723 | 6.20e-04 | 3.50e-03 | 116 |
GO:00163315 | Oral cavity | OSCC | morphogenesis of embryonic epithelium | 77/7305 | 147/18723 | 6.63e-04 | 3.72e-03 | 77 |
GO:0050730 | Oral cavity | OSCC | regulation of peptidyl-tyrosine phosphorylation | 129/7305 | 264/18723 | 6.70e-04 | 3.75e-03 | 129 |
GO:00181083 | Oral cavity | OSCC | peptidyl-tyrosine phosphorylation | 177/7305 | 375/18723 | 6.86e-04 | 3.83e-03 | 177 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0431024 | Oral cavity | NEOLP | Wnt signaling pathway | 34/1112 | 171/8465 | 8.05e-03 | 2.88e-02 | 1.81e-02 | 34 |
hsa0431034 | Oral cavity | NEOLP | Wnt signaling pathway | 34/1112 | 171/8465 | 8.05e-03 | 2.88e-02 | 1.81e-02 | 34 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SFRP2 | SNV | Missense_Mutation | novel | c.849N>G | p.Phe283Leu | p.F283L | Q96HF1 | protein_coding | tolerated(1) | benign(0.313) | TCGA-B6-A3ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
SFRP2 | insertion | Nonsense_Mutation | novel | c.772_773insAACTGTGACTTGGGTCTGGTTGGTTGTTGTTTGTTGTTTTGAG | p.Leu258GlnfsTer3 | p.L258Qfs*3 | Q96HF1 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SFRP2 | SNV | Missense_Mutation | rs774857018 | c.871N>T | p.Arg291Cys | p.R291C | Q96HF1 | protein_coding | deleterious(0.01) | probably_damaging(0.943) | TCGA-A6-3810-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SFRP2 | SNV | Missense_Mutation | c.866N>A | p.Ser289Asn | p.S289N | Q96HF1 | protein_coding | tolerated(0.06) | benign(0.076) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
SFRP2 | SNV | Missense_Mutation | rs778665160 | c.763N>A | p.Ala255Thr | p.A255T | Q96HF1 | protein_coding | tolerated(0.3) | benign(0.028) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SFRP2 | SNV | Missense_Mutation | c.99N>A | p.Phe33Leu | p.F33L | Q96HF1 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SFRP2 | SNV | Missense_Mutation | novel | c.31C>T | p.Leu11Phe | p.L11F | Q96HF1 | protein_coding | deleterious(0.02) | benign(0.054) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SFRP2 | SNV | Missense_Mutation | rs767842776 | c.265C>T | p.Pro89Ser | p.P89S | Q96HF1 | protein_coding | tolerated(0.52) | benign(0.158) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
SFRP2 | SNV | Missense_Mutation | novel | c.181N>T | p.Pro61Ser | p.P61S | Q96HF1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
SFRP2 | SNV | Missense_Mutation | rs773710868 | c.623N>A | p.Arg208Gln | p.R208Q | Q96HF1 | protein_coding | deleterious(0.01) | possibly_damaging(0.546) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |